Dimethyl Sulfoxide
Apexbio Technology LLC AZD1152 722543-31-9 10mM (in 1mL DMSO)
AZD1152 (CAS 722543-31-9) is a highly selective inhibitor of Aurora kinase a family of serine/threonine kinases involved in cancer cell proliferation It preferentially targets Aurora B kinase (IC50 0 37 nM) with lesser affinity toward Aurora A (IC50 1 37 M) and exhibits no notable activity against other kinases such as JAK2 FLT3 and Abl AZD1152 induces tumor cell cycle arrest in the G2/M phase triggers apoptosis and enhances radiosensitivity in androgen-resistant prostate cancer models In vivo AZD1152 demonstrates anti-tumor potency both alone and combined with chemotherapeutics or tubulin-targeting drugs offering a valuable research tool for oncology studies
Medchemexpress LLC Nvp-Dky709 Soltn 10Mm 1Ml Dmso | HY-144998-10MM 1ML DMSO
Nvp-Dky709 Soltn 10Mm 1Ml Dmso
Apexbio Technology LLC Pyrazinamide 98-96-4 10mM (in 1mL DMSO)
Pyrazinamide is an antimycobacterial agent primarily used in the laboratory research of tuberculosis infection As a synthetic pyrazine derivative it acts by targeting mycobacterial fatty acid synthesis pathways and disrupting bacterial membrane energetics thereby exerting bactericidal activity particularly under acidic conditions Pyrazinamide is routinely employed in in vitro cell and bacterial culture studies to investigate mechanisms of tuberculosis pathogenesis drug resistance and potential combination therapies Its inhibitory effect is usually quantified in terms of IC50 values typically ranging from approximately 10 to 60 g/mL depending on experimental conditions and mycobacterial strain types
Apexbio Technology LLC VS-5584 (SB2343) 1246560-33-7 10mM (in 1mL DMSO)
VS-5584 (SB2343 CAS 1246560-33-7) is a purine-based inhibitor targeting the mammalian target of rapamycin (mTOR) and all class I phosphoinositide 3-kinase (PI3K) isoforms (PI3K PI3K PI3K and PI3K ) It functions through ATP-competitive inhibition displaying IC50 values of 37 16 68 25 and 42 nmol/L against mTOR PI3K PI3K PI3K and PI3K respectively Through inhibition of PI3K and mTORC1/2-mediated substrate phosphorylation VS-5584 modulates the PI3K/mTOR signaling pathway frequently dysregulated in cancers In preclinical tumor xenograft studies VS-5584 has demonstrated dose-dependent inhibition of tumor growth and pathway signaling underscoring its utility in oncology research
Apexbio Technology LLC JNJ-7706621 443797-96-4 10mM (in 1mL DMSO)
JNJ-7706621 (CAS 443797-96-4) is an inhibitor targeting cyclin-dependent kinases (CDKs) and Aurora kinases specifically CDK1 (IC50 0 009 mol/L) CDK2 (0 004 mol/L) CDK3 (0 003 mol/L) CDK4 (0 058 mol/L) CDK6 (0 253 mol/L) Aurora A (0 011 mol/L) and Aurora B (0 015 mol/L) It selectively reduces proliferation of tumor cells relative to normal human cells with approximately 10-fold higher specificity Independent of cellular status of p53 retinoblastoma protein or p-glycoprotein expression JNJ-7706621 induces apoptosis suppresses colony formation and inhibits growth highlighting its utility in cancer research
Apexbio Technology LLC MI-77301 (SAR405838) 1303607-60-4 10mM (in 1mL DMSO)
MI-77301 (SAR405838 CAS 1303607-60-4) is a selective antagonist targeting the murine double minute 2 (MDM2) protein an E3 ubiquitin ligase responsible for negatively regulating tumor-suppressor p53 via ubiquitination and degradation By inhibiting the MDM2-p53 interaction (Ki 0 88 nM) MI-77301 stabilizes p53 elevates protein levels of p53 p21 and MDM2 and induces apoptosis Preclinical studies demonstrate selective growth inhibition in tumor cell lines harboring wild-type p53 (e g SJSA-1 RS4 11 LNCaP HCT-116) and potent tumor regressions in corresponding xenograft mouse models highlighting its utility for mechanistic studies and cancer therapeutic research
Apexbio Technology LLC GW788388 452342-67-5 10mM (in 1mL DMSO)
GW788388 (CAS 452342-67-5) is a selective inhibitor targeting activin receptor-like kinase 5 (ALK5) the type I receptor for transforming growth factor-beta (TGF- ) It inhibits the kinase activity of ALK5 suppressing TGF- -mediated signaling cascades GW788388 demonstrates potent inhibition of ALK5 autophosphorylation with an IC50 of 18 nM leading to decreased Smad2 phosphorylation It also inhibits TGF- -induced epithelial-mesenchymal transition (EMT) cellular proliferation fibrosis and angiogenesis in various cell models such as NMuMG MDA-MB-231 RCC and U2OS In animal studies GW788388 ameliorates renal fibrosis in diabetic db/db mouse models highlighting its utility in investigating TGF- -driven pathophysiological processes
Apexbio Technology LLC Tigecycline 220620-09-7 10mM (in 1mL DMSO)
Tigecycline is a glycylcycline-class antibiotic developed as a structural derivative of tetracycline antibiotics It exerts antimicrobial activity by reversibly binding to the bacterial 30S ribosomal subunit leading to inhibition of protein synthesis Tigecycline demonstrates bacterial growth inhibition in both Gram-positive and Gram-negative pathogens including multidrug-resistant strains In vitro studies showed minimal inhibitory concentration (MIC90) values ranging between 0 12-0 5 g/ml against vancomycin-sensitive and resistant Enterococcus faecalis and Enterococcus faecium In animal infection models using MRSA strains Tigecycline displays in vivo efficacy with an ED50 approximately 0 72 mg/kg This antibiotic is commonly employed in research studies focusing on resistant bacterial infections such as complicated skin infections and intra-abdominal infections
Apexbio Technology LLC LDC000067 1073485-20-7 10mM (in 1mL DMSO)
LDC000067 (CAS 1073485-20-7) also known as LDC067 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) CDK9 partners with cyclin T to form positive transcription elongation factor b (P-TEFb) which regulates RNA polymerase II by phosphorylating its C-terminal domain thus controlling gene transcription elongation LDC000067 inhibits CDK9 activity with an IC50 of approximately 44 10 nM Compared to other CDKs LDC000067 demonstrates notable selectivity showing 55-fold higher specificity against CDK2 and over 230-fold greater selectivity relative to CDK6 and CDK7 By selectively blocking CDK9 this ATP-competitive inhibitor reduces cellular transcription of short-lived mRNAs associated with proliferation and apoptosis such as MYC and MCL1 Thus LDC000067 is applicable in transcription regulation and cancer-related pathway studies
Apexbio Technology LLC Bedaquiline 843663-66-1 10mM (in 1mL DMSO)
Bedaquiline a diarylquinoline antibiotic targets Mycobacterium tuberculosis via dual inhibition of subunits c and within the bacterial F1FO-ATP synthase complex disrupting ATP production It is applied primarily in research addressing multi-drug resistant (MDR) tuberculosis Recent studies have expanded its use into oncology where bedaquiline inhibits mitochondrial respiratory function and reduces glycolytic activity in cancer stem-cell-like populations In vitro experiments employing breast cancer MCF7 cells revealed bedaquiline increased ROS levels and reduced mitochondrial membrane potential Reported IC50 values for growth inhibition range approximately 1-10 M depending on cell lines and experimental conditions
Apexbio Technology LLC GW0742 317318-84-6 10mM (in 1mL DMSO)
GW0742 is a synthetic selective agonist of peroxisome proliferator-activated receptor / (PPAR / ) a ligand-dependent transcription factor involved in regulating lipid metabolism inflammation and energy homeostasis Activation of PPAR / modulates downstream gene transcription influencing physiological processes including inflammatory responses and neuronal protection Experimental studies demonstrate GW0742 s role in attenuating inflammation-mediated tissue injury such as ischemia/reperfusion-induced intestinal damage as well as mitigating radiation-induced neuroinflammation and cognitive impairment in animal models Thus GW0742 serves as a research tool to study PPAR / specific pathways in inflammatory diseases metabolic processes and neuroprotective mechanisms
Apexbio Technology LLC Ivacaftor (VX-770)(Synonyms: Kalydeco, VX-770, Ivacaftor, CFTR Potentiator VX-770, Ivacaftor VX-770), 10mM (in 1mL DMSO), CAS: 873054-44-5.
Ivacaftor (VX-770 CAS 873054-44-5) is an orally bioavailable small molecule potentiator targeting the cystic fibrosis transmembrane conductance regulator (CFTR) Ivacaftor enhances CFTR-mediated chloride ion transport especially in cells expressing G551D- or F508del-CFTR mutations In vitro studies demonstrated that Ivacaftor in combination with forskolin significantly increased CFTR-dependent chloride secretion (EC50 100 nM in G551D- 25 nM in F508del-expressing cells) Similarly Ivacaftor reduced ENaC-mediated sodium reabsorption and increased airway surface liquid volume in human cystic fibrosis bronchial epithelial cells Ivacaftor is utilized in research to investigate CFTR function restoration and associated ion transport processes
Apexbio Technology LLC VX-809 936727-05-8 10mM (in 1mL DMSO)
VX-809 (CAS 936727-05-8) is a small molecule CFTR corrector that partially restores the functional expression of F508del-CFTR the most common mutation associated with cystic fibrosis (CF) VX-809 stabilizes the misfolded CFTR protein by interacting with its membrane-spanning domain 1 (MSD1) thus facilitating proper maturation and membrane localization In F508del-CFTR-expressing Fischer rat thyroid (FRT) cells VX-809 enhanced CFTR protein processing (EC50 0 1 M) and improved chloride transport (EC50 0 5 M) VX-809 is utilized predominantly as a research tool in CF studies to understand and restore CFTR function often in combination with CFTR potentiators